Ashley Nutsford

Ashley Nutsford

Auto-generated profile, based on publicly available information

Ashley Nutsford

School of Biological Sciences, University of Auckland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
ARAlex du Rand
Alex du Rand
JHJohn Hunt
John Hunt
CSChristopher Samson
Christopher Samson
ELEvert Loef
Evert Loef
CMChloe Malhi
Chloe Malhi
HSHilary (Billy) Sheppard
Hilary (Billy) Sheppard
Gene therapy based on the CRISPR/Cas9 system has emerged as a promising strategy for treating the monogenic fragile skin disorder recessive dystrophic epidermolysis bullosa (RDEB). With this approach problematic wounds could be grafted with gene edited, patient‐specific skin equivalents. Precise gene editing using homology‐directed repair (HDR) is the ultimate goal, however low efficiencies have hindered progress. Reframing strategies based on highly efficient non‐homologous end joining (NHEJ) repair aimed at excising dispensable, mutation‐harboring exons offer a promising alternative approach for restoring the COL7A1 open reading frame. To this end, we employed an exon skipping strategy using dual single guide RNA (sgRNA)/Cas9 ribonucleoproteins (RNPs) targeted at three novel COL7A1 exons (31, 68, and 109) containing pathogenic heterozygous mutations, and achieved exon deletion rates of up to 95%. Deletion of exon 31 in both primary human RDEB keratinocytes and fibroblasts resulted in the restoration of type VII collagen (C7), leading to increased cellular adhesion in vitro and accurate C7 deposition at the dermal‐epidermal junction in a 3D skin model. Taken together, we extend the list of COL7A1 exons amenable to therapeutic deletion. As an incidental finding, we find that long‐read Nanopore sequencing detected large on‐target structural variants comprised of deletions up to >5 kb at a frequency of ~10%. Although this frequency may be acceptable given the high rates of intended editing outcomes, our data demonstrate that standard short‐read sequencing may underestimate the full range of unexpected Cas9‐mediated editing events.

24 February 2026 in Journal of Virology
Verified
Journal Article
Open access
ANAshley Nutsford
Ashley Nutsford
TCThe Huong Chau
The Huong Chau
CWCarol Wang
Carol Wang
ASAsh Sargent
Ash Sargent
CCCamren Cullen
Camren Cullen
JTJohn A. Taylor
John A. Taylor
Rotaviruses (RVs) are unique among non-enveloped animal viruses encoding a structural and a nonstructural glycoprotein in their genome. The outer capsid of the virion is formed by 260 trimers of VP7, which is glycosylated at an asparagine residue(s) in the endoplasmic reticulum of infected cells, where it is retained until a late stage of virion morphogenesis. We investigated the fate of VP7 produced during synchronous infection of polarized Caco-2 cells and observed that a previously undetected form with a molecular weight greater than virion-associated VP7 was secreted into the medium. This secreted form of VP7 (sVP7) was not associated with virions and was insensitive to endoglycosidase H treatment consistent with the dominance of complex type N-glycans revealed in structural details using LC-MS/MS. We also detected core 1 and 2-type O-glycans on sVP7 contributing to the higher-than-predicted molecular weight. Purification of sVP7 from the medium of virus-infected cells revealed that it was trimeric and retained conformationally sensitive epitopes recognized by neutralizing monoclonal antibodies. Like the secreted nonstructural protein 4(NSP4), sVP7 exhibited agonism of TLR2 and TLR4 and caused activation of innate immune cells in human blood. Our results identify a novel form of the rotavirus capsid glycoprotein previously undetected and suggest that VP7 may possess extracellular functions beyond its role in the virion as a modulator of innate and adaptive antiviral immunity. IMPORTANCE: Rotavirus (RV) exhibits a mode of assembly unique among non-enveloped animal viruses whereby virion morphogenesis occurs within an endomembrane compartment. The outer shell of rotavirus is assembled within the lumen of the ER where a glycoprotein VP7 is transferred to immature particles that bud from cytoplasmic inclusions. Lytic release of virions from non-polarized cells has obscured the fate of rotavirus glycoproteins from cells with a differentiated phenotype. This study reveals that in polarized cells, a significant proportion of VP7 is secreted, independently of virions, and acquires novel glycan signatures through extensive modification of N- and O-linked glycosylation within the medial Golgi complex. Secreted VP7 exhibited agonism of Toll-like receptors and activated several distinct subsets of innate immune cells while retaining conformationally dependent neutralizing epitopes associated with a trimeric structure indicating a potential role for the secreted capsid glycoprotein in modulating both innate and adaptive immune responses to rotavirus infection.

23 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JXJinchao Xing
Jinchao Xing
QWQian Wang
Qian Wang
NCNanjun Chen
Nanjun Chen
ANAshley Nutsford
Ashley Nutsford
BSBlake Sullivan-Hill
Blake Sullivan-Hill
NNNatalie E. Netzler
Natalie E. Netzler
The phosphatidylinositol 3-kinase (PI3K) signaling pathway plays a central role in regulating key cellular processes such as survival, metabolism, and immune responses. Aberrant activation of this pathway is associated with tumorigenesis, and several PI3K inhibitors have been developed as anticancer agents. Emerging evidence suggests that viruses, including β-coronaviruses, have evolved mechanisms to exploit host PI3K signaling for their replication and immune evasion. In this study, we evaluated the antiviral efficacy of a panel of PI3K inhibitors against β-coronaviruses, including mouse hepatitis virus (MHV), human OC43 (HuCoV-OC43) and four major SARS-CoV-2 variants using both cell line and organoid models. Our findings reveal that these compounds exhibit low micromolar potency in inhibiting viral replication. Notably, the inhibitor C20 (PWT33597) demonstrated broad-spectrum activity against multiple β-coronaviruses, including SARS-CoV-2, MHV, and HuCoV-OC43, in conventional cell lines as well as in air–liquid interface (ALI)-cultured, differentiated primary human nasal and bronchial epithelial cells. Given that cytokine storm is a major contributor to SARS-CoV-2–related multiorgan failure and mortality, we further explored the impact of PI3K inhibition on host inflammatory responses. We found that MHV infection markedly increased cytokine expression in 17CL-1 fibroblasts and RAW264.7 macrophages. Interestingly, treatment with C20 further amplified cytokine production in this context, suggesting complex immunomodulatory effects that warrant further investigation. Together, our findings support the therapeutic potential of repurposing PI3K inhibitors as broad-spectrum antivirals. These compounds not only suppress viral replication but may also influence host immune responses, providing a promising avenue for intervention against current and emerging coronavirus threats.